Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Obtusifolin is a **small molecule anthraquinone derivative** found primarily in the seeds of *Senna obtusifolia* and *Senna tora*. It has demonstrated anti-inflammatory activities, notably in preclinical models of osteoarthritis and dry eye disease. Its mechanism is mainly through **inhibition of the NF-κB signaling pathway**—reducing phosphorylation of p65 and blocking the expression of downstream inflammatory mediators such as MMP3, MMP13, and COX2 in osteoarthritis[1][3]. Additionally, obtusifolin suppresses ERK/p38 MAPK signaling, further lowering pro-inflammatory cytokine levels (TNF-α, IL-6, MCP-1), and increases IL-10 production[3]. It has shown protective roles in dry eye disease by restoring tear production, reducing conjunctival irritation, and alleviating goblet cell loss[3]. In vitro, obtusifolin also inhibits high glucose-induced mitochondrial apoptosis by modulating ROS generation and apoptotic pathways in endothelial cells[7]. Investigational indications include osteoarthritis and dry eye disease; the compound is not approved for human use and is primarily used in research settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on obtusifolin.